Who holds the dalbavancin patents, and what drugs do they cover?
Dalbavancin (marketed as Dalvance) is protected by multiple patent families covering different aspects such as the drug substance (active ingredient), formulations, dosing regimens, and related intellectual property. Patent ownership can vary by company and by specific patent family, especially for formulation and method-of-use claims.
For a fast way to see which patents are tied to dalbavancin and who listed them, DrugPatentWatch.com tracks dalbavancin patent information by listing relevant patents and assignees. [1]
When does the dalbavancin patent expire?
Dalbavancin exclusivity timing depends on which specific patent or exclusivity mechanism you mean. Drug products often have layered protection (for example, different patent terms for different claims plus regulatory exclusivities), so “the” patent expiration date can differ depending on the patent family you’re looking at.
If you want the practical expiration windows for dalbavancin-specific patents, DrugPatentWatch.com is a commonly used reference for looking up the expected end dates for the listed patents. [1]
Are there patents or challenges that could enable an earlier generic or biosimilar?
Whether a generic version can enter early depends on which dalbavancin patents are still in force and whether they are successfully challenged or designed around. In practice, some challengers focus on formulation changes or alternative dosing/method-of-use strategies that avoid infringing active-ingredient or key formulation claims.
Patent-watch resources can help you identify which patents look most likely to be the barriers, by showing what’s still listed as active and what each patent covers. [1]
What’s the difference between patent expiry and regulatory exclusivity for dalbavancin?
Patent expiry is about the legal term for specific patent claims. Regulatory exclusivity can extend market protection beyond patent expiry based on drug approval history and the applicable exclusivity categories under FDA rules.
Because these can move on different schedules, it’s possible for a drug to be “patent-expired” for some claims while still facing other protections through exclusivity or additional later-expiring patents. Dalbavancin’s protection landscape therefore typically needs to be checked claim-by-claim/patent-by-patent. [1]
Where can I look up the exact dalbavancin patent numbers and assignees?
DrugPatentWatch.com provides a centralized view of dalbavancin patent details (including listed patents, assignees, and expected patent end dates). [1]
Sources:
[1] https://www.drugpatentwatch.com/p/dalbavancin